Fulgent Genetics, Inc.FLGTNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

seekingalpha.com

Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock

Fulgent Genetics offers a fortress balance sheet, zero debt, and net assets near the current share price, providing downside protection. FLGT's diagnostics business is growing, with 15.4% revenue growth YTD and all segments contributing, notably BioPharma services up 72%. Management is highly aligned, owning 33% of shares, executing opportunistic buybacks, and prioritizing disciplined M&A for further growth.

defenseworld.net

SG Americas Securities LLC Purchases New Position in Fulgent Genetics, Inc. $FLGT

SG Americas Securities LLC acquired a new position in Fulgent Genetics, Inc. (NASDAQ: FLGT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 19,167 shares of the company's stock, valued at approximately $433,000. SG Americas Securities LLC owned 0.06% of Fulgent Genetics

defenseworld.net

Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Average Rating of “Moderate Buy” from Analysts

Fulgent Genetics, Inc. (NASDAQ: FLGT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has

zacks.com

New Strong Buy Stocks for January 12th

ERO, NU, KSS, FLGT and BODI have been added to the Zacks Rank #1 (Strong Buy) List on Jan.12, 2026.

defenseworld.net

Contrasting Bullfrog AI (NASDAQ:BFRG) & Fulgent Genetics (NASDAQ:FLGT)

Bullfrog AI (NASDAQ: BFRG - Get Free Report) and Fulgent Genetics (NASDAQ: FLGT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Profitability This table compares Bullfrog AI and

defenseworld.net

Analyzing Careview Communications (OTCMKTS:CRVW) & Fulgent Genetics (NASDAQ:FLGT)

Careview Communications (OTCMKTS:CRVW - Get Free Report) and Fulgent Genetics (NASDAQ: FLGT - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Institutional and Insider Ownership 48.1% of Fulgent Genetics

zacks.com

FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform

Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.

businesswire.com

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire.

defenseworld.net

Financial Contrast: Patient Portal Technologies (OTCMKTS:PPRG) versus Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics (NASDAQ: FLGT - Get Free Report) and Patient Portal Technologies (OTCMKTS:PPRG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Risk and Volatility Fulgent Genetics has

seekingalpha.com

Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript

Fulgent Genetics, Inc. ( FLGT ) UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM EST Company Participants Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lu Li - UBS Investment Bank, Research Division Presentation Lu Li UBS Investment Bank, Research Division Great. Well, our next session is the management team from Fulgent Genetics.

businesswire.com

Fulgent to Participate in Upcoming Conferences

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10th at 5:00 PM Eastern Time Piper Sandler 37th Annual Healthcare Conference on Tuesday, December.

seekingalpha.com

Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript

Fulgent Genetics, Inc. ( FLGT ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Lu Li - UBS Investment Bank, Research Division David Westenberg - Piper Sandler & Co., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Greetings, and welcome to the Fulgent Genetics Q3 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

zacks.com

Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to earnings of $0.31 per share a year ago.

businesswire.com

Fulgent Reports Third Quarter 2025 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Results: Revenue of $84.1 million, growing 17% year-over-year GAAP loss of $6.6 million, or ($0.21) per share Non-GAAP income of $4.5 million, or $0.14 per share Adjusted EBI.

businesswire.com

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck.

businesswire.com

Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2025 financial results before the market opens on Friday, November 7, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer que.

fool.com

Fulgent Genetics: A Risky Bet or a Hidden Gem?

Explore the exciting world of Fulgent Genetics (FLGT 2.11%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

seekingalpha.com

Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)

While the stock price is unchanged since my buy rating a year ago, revenue growth is accelerating (FY25E: +14%) and gross margins are going up (FY25E: 40%, +200bps vs PY). Both precision diagnostics and anatomic pathology are positioned for sustainable double-digit revenue growth driven by innovation, increased insurance coverage, and geographic expansion. Meanwhile, Fulgent's Pharma segment continues to make steady progress, while cash burn remains moderate ($25 million in 2025).

fool.com

Fulgent (FLGT) Q2 Revenue Jumps 16%

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance